Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $184 from $183 and keeps an Overweight rating on the shares after surveying 24 ...

Highlights,A substantial portion of Neurocrine Biosciences' shares is currently held by institutional entities.,Avantax ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

Join the Southeast Missouri Team Hope Walk on April 12 at Jackson City Park to support the fight against Huntington's disease. The event raises funds for HDSA's mission to aid those affected by HD.

Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the ...